Hamburg’s Public Farewell Includes Rallying Cry For FDA Power
This article was originally published in The Rose Sheet
Executive Summary
Outgoing commissioner gives a forceful defense of the agency’s regulatory authority and warns that lowering drug approval standards would be detrimental to both patients and industry.